PulseAugur
EN
LIVE 09:05:34

iRegene Therapeutics secures $29M for AI-driven cell therapy platform

By PulseAugur Editorial · [1 sources] ·

iRegene Therapeutics has secured 210 million yuan (approximately $29 million) in a Series C1 funding round. The company plans to utilize these funds to further develop its AI-powered platform, which focuses on creating universal cell therapies for age-related diseases. AI

IMPACT Accelerates development of AI-driven therapies for age-related diseases, potentially improving treatment outcomes.

RANK_REASON Significant funding round for an AI-focused biotech company. [lever_c_demoted from significant: ic=1 ai=0.7]

Read on Pandaily →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

iRegene Therapeutics secures $29M for AI-driven cell therapy platform

COVERAGE [1]

  1. Pandaily TIER_1 English(EN) · [email protected] (Pandaily) ·

    iRegene Therapeutics Raises 210M Yuan in Series C1 for AI-Powered Cell Therapy Platform

    iRegene Therapeutics completed a 210 million yuan ($29 million) Series C1 financing round to advance its AI-driven chemical induction platform for universal cell therapies targeting age-related diseases.

RELATED TOPICS